SELLAS Life Sciences reports Phase 3 leukemia survival benefit
REGAL recorded median survival of 24.0 months versus 14.7 months on best available treatment, with a biologics filing planned for 2027.

A pivotal leukemia trial met its survival endpoint as SELLAS Life Sciences Group, Inc. NASDAQSLS reported median survival of 24.0 months with galinpepimut-S versus 14.7 months on best available treatment on Tuesday. The Phase 3 REGAL result supports its planned biologics application in the first half of 2027.
The Nov. 17 release put the hazard ratio at 0.59, representing a 41 per cent reduction in the risk of death. The two-sided p value was 0.035, and the analysis followed 80 deaths under a prespecified statistical plan.
SELLAS is a New York-based clinical-stage biopharmaceutical company developing treatments for cancer.
Shares last closed at US$7.47 on Nasdaq at 4:00 p.m. EST on Nov. 16, according to Google Finance's NASDAQSLS page. That close preceded Tuesday's results and provides no measure of the market's response to the readout.
The trial registry lists actual enrollment of 127 and an open-label design, with one-to-one randomization between GPS, as the vaccine is known, and investigator-selected care. The registry record was last updated Oct. 1, 2025.
Participants had achieved a second or later remission after salvage therapy and were ineligible for, or unable to undergo, an allogeneic stem cell transplant. The trial also admitted patients whose remission came with insufficient platelet recovery.
Control options included observation, azacitidine, decitabine, venetoclax or low-dose cytarabine, alone or in permitted combinations. The comparator therefore represented a choice of care rather than a single drug regimen.
SELLAS reported predominantly mild or moderate treatment-related adverse events, most commonly injection-site reactions, and no new safety signals. It said prognostic factors were balanced between arms, as were the few patients who later underwent transplantation.
"Patients with AML in second remission who cannot undergo allogeneic stem cell transplantation face poor survival outcomes and have a significant need for new treatment approaches," the REGAL study steering committee said in the release.
Onureg Treats Patients In First Remission
An established AML treatment after remission is Onureg from Bristol Myers Squibb NYSEBMY. Its Sept. 1, 2020 approval release specifies adults in first remission after intensive induction chemotherapy who cannot complete intensive curative therapy.
REGAL studied second or later remissions, so the programs address different treatment settings. The separate studies do not establish how GPS would perform against Onureg.
The State Street SPDR S&P Biotech ETF NYSEARCAXBI, a broader sector benchmark, was US$145.88 at 8:00 p.m. EST on Nov. 16, according to Google Finance's NYSEARCAXBI page.
SELLAS said evaluation of secondary endpoints and other prespecified analyses remained underway on Nov. 17. It plans to present detailed results at a major medical conference and submit them for publication in a peer-reviewed journal.
SELLAS plans to discuss an accelerated filing strategy with the U.S. Food and Drug Administration. The topline regulatory update does not describe prior FDA feedback on the trial design or an agency assessment of the completed study.
Read more: Summit Therapeutics reports FDA refusal for lung cancer treatment
Cash Supports Filing Preparations
SELLAS reported US$134.7 million in cash and cash equivalents at Sept. 30 in its Nov. 12 financial update. The cash-position section did not specify how long that balance would fund operations.
Research and development expenses rose to US$7.0 million in the third quarter of 2026 from US$4.2 million a year earlier. SELLAS attributed the increase primarily to manufacturing, clinical and regulatory consulting, and trial expenses in preparation for a potential GPS application.
Read more: Kyverna Therapeutics completes miv-cel BLA for stiff person syndrome
SELLAS plans to submit its GPS biologics application in the first half of 2027 after discussing the results with the FDA. The proposed submission would seek approval for maintenance treatment in the population studied in REGAL.
Adrian Kessler






